GLP1R and cardiovascular disorder: Although several clinical trials have revealed that GLP-1 receptor agonists reduce the risk of cardiovascular disease in patients with diabetes [42,43,44], the effect of the GIP receptor agonist, including tirzepatide, on atherosclerotic cardiovascular disease remains unclear.